CompletedNCT01259492
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Medication studyAges 18–60Multiple countries
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 67 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 725
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Belgium, Colombia, ...
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01259492
- Official title
Show the full official title
A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD
Recruitment & locations
CompletedLittle Rock, United States · Beverly Hills, United States · Spring Valley, United States
61 more locations
- Bradenton, United States
- Miami, United States
- Orlando, United States
- West Plam Beach, United States
- Libertyville, United States
- Owensboro, United States
- Troy, United States
- Las Vegas, United States
- Willingboro, United States
- Fargo, United States
- Columbus, United States
- Oklahoma City, United States
- Philadelphia, United States
- Houston, United States
- Bellevue, United States
- Seattle, United States
- Bruges, Belgium
- Heusden-Zolder, Belgium
- Kortenberg, Belgium
- Uccle, Belgium
- Kessel-Lo, Belgium
- Mechelen, Belgium
- Santa Fe de Antioquia, Colombia
- Antioquia, Colombia
- Bogotá, Colombia
- Århus C, Denmark
- Ahrensburg, Germany
- Bamberg, Germany
- Berlin, Germany
- Essen, Germany
- Hamburg, Germany
- Kiel, Germany
- Ludwigsburg, Germany
- Mainz, Germany
- München, Germany
- Naumburg, Germany
- Nuremberg, Germany
- Wolfsburg, Germany
- Dresden, Germany
- Ellwangen, Germany
- Freiburg im Breisgau, Germany
- Hagen, Germany
- Hanover, Germany
- Homburg, Germany
- Landau, Germany
- Leipzig, Germany
- Limburg, Germany
- Mannheim, Germany
- Siegen, Germany
- Ulm, Germany
- Westerstede/Oldenburg, Germany
- Würzburg, Germany
- Porsgrunn, Norway
- Skien, Norway
- Singapore, Singapore
- Benoni, South Africa
- Melrose Arch, South Africa
- Pretoria, South Africa
- Luleå, Sweden
- Malmö, Sweden
- Stockholm, Sweden
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Placebo, Ritalin LA 20 mg and Ritalin LA 30 mg.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )